Two cancer stem cell-targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model.

Stem Cells Transl Med · 2020 · PMC7381803 · PMID 32281289

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Analysis of post‐treatment samples revealed a highly significant reversal of a stemness gene expression signature that was observed in pretreatment CLL cells. 38 Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor that blocks B‐cell receptor signaling, is an effective therapy for patients with CLL although it does not completely eradicate disease. 40

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.